Engineered graphene quantum dot nanocomposite triggers α-synuclein defibrillation: Therapeutics against Parkinson's disease

• Published in: Nanomedicine 2023-01, Vol.47, p.102608-102608, Article 102608
• Main Authors: Kaliyaperumal, Poonkuzhali, Renganathan, Seenivasagan, Arumugam, Karthika, Aremu, Bukola Rhoda
• Format: Article
• Language: English
• Subjects: alpha-Synuclein; Animals; Graphene quantum dot; Graphite; Mice; Mice, Inbred C57BL; Neuroblastoma; Parkinson Disease - drug therapy; Parkinson's disease; Simulation; α-Synuclein
• ISSN: 1549-9634; 1549-9642
• DOI: 10.1016/j.nano.2022.102608

Emerging clinically required α-synuclein (α-syn) inhibitor which acts as a neuroprotective nanocomposite drug is in increased demand as a patient-safe central nervous system therapeutic. This inhibitor is intended to chemically engineer graphene quantum dot (GQD) with blue luminescence, and stands to be a potential cure for Parkinson's disease. It has been theorized that α-syn aggregation is a critical step in the development of Parkinson's. Hence narrow the target by α-syn inhibition, through chemically synthesize methyl N-allyl N-benzoylmethioninate (MABM) and functionally engineer the surface of GQD to target the brain delivery on C57BL/6 mice. Spectroscopic and simulation studies confirm defibrillation through the interaction between N-terminal amino acids and MABM-GQD nanoparticles, which makes nontoxic α-syn. Therefore, this drug's ability to cross the blood-brain barrier in vitro functionally prevents neuronal loss in neuroblastoma cells. Thus, in vivo cerebral blood flow analysis using magnetic resonance imaging illustrates, how this nanocomposite can possibly treat Parkinson's. Parkinson's disease caused by α-synuclein protein fibrils storage in brain is a pathogenic hallmark for neurodegenerative disorders. We designed and chemically engineered the graphene quantum dot (GQD) using synthesized organic novel compound named methyl N-allyl N-benzoylmethioninate (MABM). MABM loaded GQD nanoparticles exhibit good in vitro α-synuclein defibrillation activity. The targeted delivery of nanocomposite effect in vitro Blood brain barrier model possesses excellent crossing ability of drug. In vivo Magnetic resonance imaging cerebral blood flow studies confirms that nanocomposite cure Parkinson's disease neurodegeneration through α-synuclein defibrillation. [Display omitted]